FDA Panel Recommends Approval For Savient's Gout Treatment

A Food and Drug administration advisory panel recommended approval for Savient Pharmaceuticals Inc.'s (Nasdaq: SVNT) gout treatment prompting an upgrade. The stock price leaped $3.36 to $12.63.


About this Entry

This page contains a single entry by published on June 17, 2009 10:38 AM.

Earnings Drop For A-Power was the previous entry in this blog.

Reynolds Did Not Infringe On Star Scientific's Patents is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12